Bottom line: called out once again on obscuring the facts and PBT2 is one of two drugs that made it on top through 2500 compounds tested so far in the dish. PBT2 hits multiple AD target intervention points based on testing in the dish. And the real kicker is improvement in neuronal viability. Something no other drug showed either.
Tanzi will put up a peer-reviewed paper in a high impact journal to document the results of PBT2 testing in the dish. Then you will have to work hard to obscure the facts and deride that and I will be here to take your insults and lies down.
AAIC 2016 talks, page-69
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
-0.001(25.0%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.3¢ | $4.734K | 1.341M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 49 | 30295639 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 129917446 | 34 |
View Market Depth
| Last trade - 15.44pm 15/10/2024 (20 minute delay) ? |
| ATH (ASX) Chart |